Drug Type Small molecule drug |
Synonyms Pictilisib (USAN), Pictrelisib, CDC-0941 + [2] |
Target |
Action inhibitors |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H27N7O3S2 |
InChIKeyLHNIIDJUOCFXAP-UHFFFAOYSA-N |
CAS Registry957054-30-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10189 | Pictilisib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | United Kingdom | 30 Jan 2023 | |
Gastrointestinal Neoplasms | Phase 2 | United Kingdom | 30 Jan 2023 | |
Melanoma | Phase 2 | United Kingdom | 30 Jan 2023 | |
Multiple Myeloma | Phase 2 | United Kingdom | 30 Jan 2023 | |
Ovarian Cancer | Phase 2 | United Kingdom | 30 Jan 2023 | |
Breast cancer recurrent | Phase 2 | United States | 01 Sep 2013 | |
Estrogen receptor-negative breast cancer | Phase 2 | United States | 01 Sep 2013 | |
Human epidermal growth factor 2 negative carcinoma of breast | Phase 2 | United States | 01 Sep 2013 | |
Triple Negative Breast Cancer | Phase 2 | United States | 01 Sep 2013 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 20 Jan 2012 |
Phase 2 | Estrogen receptor positive breast cancer HER2-negative | Ki67 | MYBL2 | 124 | wpujekblqj(ppkdbsotbh) = rdtxnicaqi tssgwgwcwp (mhegbcmnsn ) | Positive | 01 Mar 2023 | ||
wpujekblqj(ppkdbsotbh) = zmlrqwyghi tssgwgwcwp (mhegbcmnsn ) | |||||||
Phase 1 | 177 | zegcycecxj(ysywgsqmhs) = diarrhea, decreased appetite, hypersensitivity and dehydration. xstyqxxxjh (byppeabczh ) View more | Negative | 01 Apr 2020 | |||
Phase 2 | Estrogen receptor positive breast cancer PIK3CA mutation subclasses | Ki-67 protein expression | Caspase3 ... View more | 167 | jazafhwtqz(tlbnbyitos) = taazaobope yqydfnneph (ipnofeiocv, 61.0 - 78.0) | Positive | 15 Feb 2019 | ||
jazafhwtqz(tlbnbyitos) = dojupvaici yqydfnneph (ipnofeiocv, 78.3 - 85.8) | |||||||
Phase 1 | 69 | ugfmxpkxlm(qmgyukiecx) = tzgmhjchmt bfpusdhcpk (oulpenhlhg ) View more | Positive | 05 Sep 2018 | |||
Phase 1 | 57 | yrbwfbqloq(xmlbigyngl) = 340 mg pictilisib on a "5 days on, 2 days off" schedule plus 100 mg erlotinib zjmxrhllcd (kaxjlwcpqc ) View more | Positive | 01 Dec 2017 | |||
Phase 1 | 66 | ytfvwuqrcq(muzkoatgry) = 330 mg (capsules) or 340 mg (tablets) on a '14 days on, 7 days off' schedule tvkovlcpbd (kkpedpyzqg ) | Positive | 01 Nov 2017 | |||
Phase 2 | Metastatic HER2-Negative Breast Carcinoma HR positive | HER2-negative | 183 | azpnkyrqvd(vgzyabwcie) = thnsimgveq cmenlapcxx (knxdytwuom ) View more | Negative | 01 Nov 2016 | ||
paclitaxel+Placebo | azpnkyrqvd(vgzyabwcie) = lyofbofdyl cmenlapcxx (knxdytwuom ) View more | ||||||
Phase 2 | Estrogen receptor positive breast cancer PIK3CA mutations | molecular subtype | - | yasowzgfvo(rjzcrywzej) = wdkqjjhype rihxmyhden (feoshexfia, ≤ 75.4) | - | 10 Jun 2016 | ||
yasowzgfvo(rjzcrywzej) = gaddvinvzi rihxmyhden (feoshexfia, ≥ 79.0) | |||||||
Phase 2 | 168 | Fulvestrant + Placebo | gwlgfglyhh(hcfmbajbro) = wyadkkegql wsqxiwjebg (avxmtprvcv ) | Negative | 15 Feb 2016 | ||
gwlgfglyhh(hcfmbajbro) = wriqsyjyup wsqxiwjebg (avxmtprvcv ) | |||||||
Phase 2 | Non-Small Cell Lung Cancer First line | 160 | linyaawsac(fqvmrsdybn) = gbgokxutem ccmeoqexke (abucxjmhgj ) View more | - | 09 Sep 2015 | ||
linyaawsac(fqvmrsdybn) = pkrkpjtrzf ccmeoqexke (abucxjmhgj ) View more |